Professional Documents
Culture Documents
Or
Basic
Biopharmaceutics
Clinical Trials
10-15 years from lab to US patients
Only 1 in 5000 compounds make it to human
testing
Only 1 in 5 tested in humans is approved
Testing Phases in Humans
Phase I (ADME)
Phase II (w/dz)
Phase III (Special study)
Phase IV (post-mkt)
Generic Medications
Patent on parent agent
Hatch-Waxman Act 1984
Pharmaceutical Co
ANDA filed with FDA
Bioequivalent
Labeling Review
Pharmaceutically equiv.
Therapeutically equiv.
Receptors
Cellular material at the
site of action
Lock & key
Agonist
Antagonist
.OR
The time taken for 50% of the drug to be
eliminated
The time taken for the drug concentration to
fall to half the original value
After 4 half lives, elimination is 94% complete
After 7 half lives, elimination is 99% complete
After 1 half life, elimination is_____complete
Bioequivalence Terms
Bioavailability
Bioequivalency
Pharmaceutical
equivalent
Pharmaceutical
alternative
Therapeutic equivalent
Pharmacokinetics
How a drug Moves
What the body does to
a drug
ADME
Absorption
Distribution
Metabolism
Excretion
Diffusion
Passive diffusion
Active transport
Pharmacodynamics
How a drug Behaves
What the drug does to
the body
Beneficial
Toxic
Absorption
Gastric emptying
Intestinal movement
rate
Distribution
Blood flow rate
Permeability of tissue
membranes
Protein binding
Metabolism
Liver
Enzyme induction
Enzyme inhibition
Gall bladder
Stores metabolites
Enterohepatic cycling
First-Pass metabolism
Excretion
Kidneys
Nephron
Glomerular filtration
rate
Hematological effects
Drug dependence
Teratogenicity
Carcinogenicity
Idiosyncrasy
Drug-Drug Interactions
Absorption
Distribution
Binding in
GIT
GI empty
Displacemt Enzyme
induction
and effect
Gastric pH
Intestinal
Metabolism
Metabolism
Enzyme
inhibition
Excretion
GFR
Renal
Secretion
Urinary Reabsorption
Drug-Diet Interactions
Absorption
Distribution
Metabolism
Food
Food Mix
Protein
Carbohydrate
Fat
Calories
Excretion
Protein
Inc.GFR
Dec.reabsorption
Dec.secretion in
the kidney
Hepatic
Circulatory
Renal
Thyroid
Cirrhosis
Obstructive
jaundice
Acute viral
hepatitis
Cardiovascular
Disorders
Decrease Blood
Flow
erratic absorptn
liver metabolm
Effect on drug
Hypo- Hyperelimination
Effect on plasma
protein binding
Creatinine levels
CASE STUDY!